Travere Therapeutics Inc (NASDAQ:TVTX) currently has a daily average trading volume of 1.11M but it saw 914013 shares traded in last market. With a market cap of 664.70M USD, the company’s current market price of $8.69 came falling about -2.36 while comparing to the previous closing price of $8.90. In past 52 weeks, the stock remained buoying in the range of price level as high as $15.39 and as low as $5.12. In the recent trading on the day, stock has struck highest price mark of $8.64 while lowest mark touched by it was $9.1571.
Taking a look at 20-day trading activity of Travere Therapeutics Inc (TVTX) gives us an average price of $9.01, while its current price level is -43.53% below from 52-week high level whereas it is 69.73% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $8.74 while that of 200 days or SMA-200 reads an average of $7.81. A closer look into the stock’s movement over the week reveals that its volatility is standing at 4.44% during that period while stretching the period over a month that increases to 6.87%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 46.52 which implies that the stock is in neutral territory.
Citigroup upgraded its recommendation for the stock as a “Buy” from “Neutral” on December 05, 2023 while assigning a price target range of $7-$10. Citigroup issued its recommendations for the stock as it initiated the price target for the stock is $7.
Over the week, TVTX’s stock price is moving 1.88% up while it is -11.15% when we observe its performance for the past one month. Year-to-date it is -3.34% down and over the past year, the stock is showing a downside performance of -34.17%.
The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of 1.97 beat the consensus estimate of -0.14 for the same. The company is expected to be releasing its next quarterly report on 2024-Nov-05, for which analysts forecasted an EPS of -0.7 while estimate for next year EPS is -3.72. In next quarter, company is expected to be making quarterly sales of $65.57M as analysts are expecting the sales for current fiscal year at $224.25M and seeing the company making $336.7M in sales next year. Moreover, analysts are in estimates of $60.67M for current-quarter revenue.
Currently, Travere Therapeutics Inc’s total number of outstanding shares is 76.49M with 0.73% of that held by the insiders while 117.29% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -90.01% and return on equity (ROE) at -582.60%. Stock’s beta reads 0.71. Stock has a price to book (P/B) ratio of 43.86 while price to sale or P/S ratio amounts to 3.74. Its return on asset (ROA) is -59.56% on average.
